Madrigal Unveils Positive Topline Data for Investigational NASH Therapy

Madrigal Pharmaceutical’s investigational drug resmetirom reduced liver fat by up to 48 percent over one year, raising hopes of a first-in-class approval for nonalcoholic steatohepatitis (NASH), company executives said yesterday.
Source: Drug Industry Daily